Osteoporosis International

, Volume 21, Issue 11, pp 1853–1861 | Cite as

Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease

  • P. Manghat
  • W. D. Fraser
  • A. S. Wierzbicki
  • I. Fogelman
  • D. J. Goldsmith
  • G. Hampson
Original Article



We investigated the association between fibroblast growth factor-23 (FGF-23) and (1) the biochemical parameters implicated in chronic kidney disorder (CKD)-bone and mineral disorder (CKD-MBD) and (2) bone mineral density (BMD) in patients with CKD 1-4. C-reactive protein (CRP) and serum phosphate correlated with FGF-23. A significant association was seen between FGF-23 and BMD at the hip.


Circulating FGF-23 is elevated in CKD, although the primary stimulus remains unclear. Moreover, it is still unknown whether increase in FGF-23 has a biological effect on bone metabolism. The aim of the study was to investigate the association of FGF-23 with (1) the biochemical parameters linked with CKD-bone and mineral disorder (CKD-MBD) and (2) bone mineral density in CKD.


We studied 145 patients (74 M, 71 F) aged (mean [SD]) 53 [14] years with CKD 1–4. Serum calcium, phosphate, parathyroid hormone, FGF-23, 25 (OH) vitamin D, 1, 25 (OH)2 vitamin D, bone turnover markers, CRP were determined. BMD was measured at the lumbar spine, femoral neck (FN), forearm, and total hip (TH). Multivariate analysis was undertaken to explore the association between (1) the biochemical variables and FGF-23 and (2) FGF-23 and BMD.


Elevations in FGF-23 occurred in CKD stage 3 compared to CKD stage 1/2, although no significant differences in serum phosphate were observed. Serum phosphate (p < 0.001), CRP (p < 0.001) and diabetes mellitus (p < 0.05) were associated with FGF-23. BMD Z-score was significantly lower at the TH and FN in CKD 4 (p < 0.05). A significant association was seen between BMI, FGF-23, bone specific alkaline phosphatase and BMD at the TH (p < 0.05).


The data suggest that FGF-23 may be associated with parameters implicated in the complications of CKD. Longitudinal studies are required for further clinical evaluation.


Bone mineral density Chronic kidney disease Fibroblast growth factor-23 


Conflicts of interest



  1. 1.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953CrossRefPubMedGoogle Scholar
  2. 2.
    KDIGO (2009) Clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76(Suppl 113):S22–S49Google Scholar
  3. 3.
    Kovesdy CP, Kalanter-Zadeh K (2008) Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 40:427–440CrossRefPubMedGoogle Scholar
  4. 4.
    Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315CrossRefPubMedGoogle Scholar
  5. 5.
    Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549CrossRefPubMedGoogle Scholar
  6. 6.
    Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto KI (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288:E1101–E1109CrossRefPubMedGoogle Scholar
  7. 7.
    Yu X, Sabbagh Y, Davis SI, Demay MB, White KE (2005) Genetic dissection of phosphate and vitamin D -mediated regulation of circulating FGF-23 concentrations. Bone 36:971–977CrossRefPubMedGoogle Scholar
  8. 8.
    Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120–1125CrossRefPubMedGoogle Scholar
  9. 9.
    Juppner H (2007) Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 11(Suppl 1):S3–S22CrossRefPubMedGoogle Scholar
  10. 10.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol Jul 16(7):2205–2215CrossRefGoogle Scholar
  11. 11.
    Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE (2007) Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 22(11):3202–3207CrossRefPubMedGoogle Scholar
  12. 12.
    Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256CrossRefPubMedGoogle Scholar
  13. 13.
    Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D (2008) Bone mass does not correlate with the serum fibroblast growth factor-23 in hemodialysis patients. Kidney Int 73(1):102–107CrossRefPubMedGoogle Scholar
  14. 14.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584–592CrossRefPubMedGoogle Scholar
  15. 15.
    Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ (2005) C-reactive protein and albumin as predictors of all cause and cardiovascular mortality in chronic kidney disease. Kidney Int 68:766–772CrossRefPubMedGoogle Scholar
  16. 16.
    Stenvinkel P, Alvestrand A (2002) Inflammation in end-stage renal disease: sources, consequences and therapy. Sem Dial 15:329–337CrossRefGoogle Scholar
  17. 17.
    Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B (2008) Genetic evidence of serum phosphate-independent functions of fgf-23 on bone. PLOS Genetics 4(8):e10000154CrossRefGoogle Scholar
  18. 18.
    Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948CrossRefPubMedGoogle Scholar
  19. 19.
    Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, Pound S, Rappaport I, Robertson D, Semple Y, Slane P, Whitworth C, Williams B (2007) UK consensus conference on early chronic kidney disease—6 and 7 february 2007. Nephrol Dial Transplant 22(9):2455–2457CrossRefPubMedGoogle Scholar
  20. 20.
    Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP (2008) Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 23(5):721–729CrossRefPubMedGoogle Scholar
  21. 21.
    Quarles LD (2008) Endocrine functions of bone in mineral metabolism. J Clin Invest 118:3820–3928CrossRefPubMedGoogle Scholar
  22. 22.
    Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K (2009) Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone. doi: 10.1016/j.bone.2009.08.008 PubMedGoogle Scholar
  23. 23.
    Daji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T (2009) Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron 111:61–68CrossRefGoogle Scholar
  24. 24.
    Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M (2005) Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101(2):94–99CrossRefGoogle Scholar
  25. 25.
    Stubbs J, Liu S, Quarles LD (2007) Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 20(4):302–308CrossRefPubMedGoogle Scholar
  26. 26.
    Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67(3):1171–1178CrossRefPubMedGoogle Scholar
  27. 27.
    Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65(5):1943–1946CrossRefPubMedGoogle Scholar
  28. 28.
    Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Geyjo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 67(3):1120–1125CrossRefPubMedGoogle Scholar
  29. 29.
    Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683–2688CrossRefPubMedGoogle Scholar
  30. 30.
    Lavi-Moshayoff V, Silver J, Naveh-Many T (2009) Human PTH gene regulation in vivo using transgenic mice. Am J Physiol Renal Physiol 297:F713–F719CrossRefPubMedGoogle Scholar
  31. 31.
    Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M (2004) Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44:481–487PubMedGoogle Scholar
  32. 32.
    Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes Prac Patterns Study. Kidney Int 67:1179–1187CrossRefPubMedGoogle Scholar
  33. 33.
    Toussaint ND, Kerr PG (2007) Vascular calcification and arterial stiffness in chronic kidney disease; implications and management. Nephrology 12:500–509CrossRefPubMedGoogle Scholar
  34. 34.
    KDIGO (2009) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76(Suppl 113):S50–S99Google Scholar
  35. 35.
    Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24(3):948–955CrossRefPubMedGoogle Scholar
  36. 36.
    Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFillipi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552CrossRefPubMedGoogle Scholar
  37. 37.
    Iseki K, Kohagura K (2007) Anemia as a risk factor for chronic kidney disease. Kidney Int 72:S4–S9CrossRefGoogle Scholar
  38. 38.
    Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C (2005) Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction and myocardiopathy in patients with ESRD. Kidney Int 67:2330–2337CrossRefPubMedGoogle Scholar
  39. 39.
    Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K (2008) Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 40:1067–1074CrossRefPubMedGoogle Scholar
  40. 40.
    Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H (2009) The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone. doi: 10.1016/j.bone.2009.07.016 Google Scholar
  41. 41.
    Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG (2007) Ablation of vitamin D signalling rescues bone, mineral and glucose homeostasis in FGF-23 deficient mice. Matrix Biology 26:75–84CrossRefPubMedGoogle Scholar
  42. 42.
    Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P (2007) Pulse wave velocity is inversely related to vertebral bone density in haemodialysis patients. Hypertension 49:1278–1284CrossRefPubMedGoogle Scholar
  43. 43.
    Toussaint ND, Lau KK, Strauss BJ, Kevan R, Polkinghorne KR (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23:586–593CrossRefPubMedGoogle Scholar
  44. 44.
    Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB (2009) Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94(2):511–517CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • P. Manghat
    • 1
  • W. D. Fraser
    • 2
  • A. S. Wierzbicki
    • 1
  • I. Fogelman
    • 3
  • D. J. Goldsmith
    • 4
  • G. Hampson
    • 1
  1. 1.Department of Chemical Pathology5th Floor, North Wing, St Thomas’ HospitalLondonUK
  2. 2.Department of Clinical ChemistryRoyal Liverpool HospitalLiverpoolUK
  3. 3.Department of Nuclear MedicineGuy’s HospitalLondonUK
  4. 4.Renal UnitGuy’s HospitalLondonUK

Personalised recommendations